Genomic Health, Inc. (NASDAQ:GHDX) saw a significant drop in short interest in January. As of January 12th, there was short interest totalling 683,665 shares, a drop of 24.9% from the December 29th total of 910,922 shares. Based on an average daily trading volume, of 176,436 shares, the days-to-cover ratio is presently 3.9 days. Approximately 2.0% of the shares of the stock are short sold.

Shares of Genomic Health (NASDAQ:GHDX) opened at $32.58 on Friday. The company has a market capitalization of $1,130.00, a PE ratio of -250.62 and a beta of 0.59. Genomic Health has a 12-month low of $26.54 and a 12-month high of $37.50.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Wednesday, November 8th. The medical research company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. The firm had revenue of $83.82 million during the quarter, compared to analyst estimates of $87.06 million. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%. equities research analysts expect that Genomic Health will post -0.08 EPS for the current fiscal year.

A number of analysts have recently weighed in on the company. BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. William Blair lowered Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Barclays restated a “sell” rating and issued a $28.00 target price on shares of Genomic Health in a research note on Monday, January 8th. Canaccord Genuity reiterated a “buy” rating and issued a $42.00 price objective on shares of Genomic Health in a research report on Tuesday, January 16th. Finally, Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $32.33.

In other news, insider Laura Leber sold 21,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $33.29, for a total value of $699,090.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $31.47, for a total value of $157,350.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,338 shares of company stock valued at $2,463,301. 46.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its holdings in Genomic Health by 1.3% during the second quarter. Bank of New York Mellon Corp now owns 89,714 shares of the medical research company’s stock worth $2,921,000 after buying an additional 1,137 shares during the last quarter. Legal & General Group Plc boosted its holdings in Genomic Health by 11.4% during the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after buying an additional 710 shares during the last quarter. Swiss National Bank boosted its holdings in Genomic Health by 8.7% during the second quarter. Swiss National Bank now owns 33,900 shares of the medical research company’s stock worth $1,103,000 after buying an additional 2,700 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Genomic Health by 18.2% during the second quarter. Wells Fargo & Company MN now owns 61,075 shares of the medical research company’s stock worth $1,987,000 after buying an additional 9,391 shares during the last quarter. Finally, Teachers Advisors LLC boosted its holdings in Genomic Health by 10.6% during the second quarter. Teachers Advisors LLC now owns 35,177 shares of the medical research company’s stock worth $1,145,000 after buying an additional 3,376 shares during the last quarter. Hedge funds and other institutional investors own 89.75% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/03/short-interest-in-genomic-health-inc-ghdx-declines-by-24-9.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.